Article Text

Download PDFPDF
Extended report
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
  1. Mark C Genovese1,
  2. Patrick Durez2,
  3. Hanno B Richards3,
  4. Jerzy Supronik4,
  5. Eva Dokoupilova5,
  6. Vadim Mazurov6,
  7. Jacob A Aelion7,
  8. Sang-Heon Lee8,
  9. Christine E Codding9,
  10. Herbert Kellner10,
  11. Takashi Ikawa11,
  12. Sophie Hugot3,
  13. Shephard Mpofu3
  1. 1Department of Rheumatology, Stanford University, Palo Alto, California, USA
  2. 2Université Catholique de Louvain, Brussels, Belgium
  3. 3Novartis Pharma AG, Basel, Switzerland
  4. 4NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland
  5. 5Medical Plus, Uherske Hradiste, Czech Republic
  6. 6St. Petersburg State Medical Academy of Postgraduate Education, St Petersburg, Russia
  7. 7The Arthritis Clinic, Jackson, Tennessee, USA
  8. 8Konkuk University Medical Center, Seoul, Republic of Korea
  9. 9Health Research of Oklahoma, Oklahoma City, Oklahoma, USA
  10. 10Department of Rheumatology, Hospital Neuwittelsbach, Munich, Germany
  11. 11Konan Yamate Clinic, Kobe, Hyogo, Japan
  1. Correspondence to Dr Mark C Genovese, Division of Immunology and Rheumatology, Stanford University, 1000 Welch RD #203, Palo Alto, CA 94304, USA; genovese{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.